{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sandostatin+LAR",
    "query": {
      "intervention": "Sandostatin LAR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sandostatin+LAR&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T19:41:37.685Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01707225",
      "title": "Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Bleeding"
      ],
      "interventions": [
        {
          "name": "Octreotide LAR Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-02",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-02-03",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01707225"
    },
    {
      "nct_id": "NCT01538966",
      "title": "Acromegaly Combination Treatment Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "Pegvisomant",
          "type": "DRUG"
        },
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        },
        {
          "name": "Lanreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 76,
      "start_date": "2012-03-29",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01538966"
    },
    {
      "nct_id": "NCT06784752",
      "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Somatostatin Receptor Positive (SSTR+)",
        "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "RADIATION"
        },
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 240,
      "start_date": "2025-05-30",
      "completion_date": "2034-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784752"
    },
    {
      "nct_id": "NCT02916433",
      "title": "Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Octreotide",
        "Sputum"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Danbury Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2016-09",
      "completion_date": "2019-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 1,
      "location_summary": "Danbury, Connecticut",
      "locations": [
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02916433"
    },
    {
      "nct_id": "NCT00002864",
      "title": "Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "octreotide acetate",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "Up to 120 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "1996-09-24",
      "completion_date": "2010-04-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 2,
      "location_summary": "Duluth, Minnesota",
      "locations": [
        {
          "city": "Duluth",
          "state": "Minnesota"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002864"
    },
    {
      "nct_id": "NCT01424241",
      "title": "Effects of Sandostatin LAR® in Acromegaly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "Sandostatin LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2006-10",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01424241"
    },
    {
      "nct_id": "NCT01121939",
      "title": "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Sandostatin LAR® Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2010-05",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-02-05",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 9,
      "location_summary": "Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01121939"
    },
    {
      "nct_id": "NCT00092287",
      "title": "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "lanreotide Autogel (somatostatin analogue)",
          "type": "DRUG"
        },
        {
          "name": "Sandostatin long acting release (LAR) Depot (somatostatin analogue)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2004-07",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2020-04-30",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00092287"
    },
    {
      "nct_id": "NCT03972488",
      "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Lutathera",
          "type": "DRUG"
        },
        {
          "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)",
          "type": "DRUG"
        },
        {
          "name": "2.5% Lys-Arg sterile amino acid solution",
          "type": "DRUG"
        },
        {
          "name": "High dose 60 mg octreotide long-acting repeatable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2020-01-08",
      "completion_date": "2027-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972488"
    },
    {
      "nct_id": "NCT03289741",
      "title": "A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "LAR Lanreotide",
          "type": "DRUG"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2017-09-19",
      "completion_date": "2023-04-10",
      "has_results": true,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-09-03T19:41:37.685Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289741"
    }
  ]
}